T1	Participants 141 186	in adults with severe hemophilia A (SPINART)
T2	Participants 340 373	in older patients with hemophilia
T3	Participants 702 708	trial.
T4	Participants 709 929	Males aged 12-50 years with severe hemophilia A, ≥ 150 days of exposure to FVIII, no FVIII inhibitors, no prophylaxis for > 12 consecutive months in the past 5 years and 6-24 bleeding episodes in the preceding 6 months
T5	Participants 1364 1498	RESULTS Eighty-four patients were enrolled and analyzed (n = 42 per group; mean age, 30.6 years; median treatment duration, 1.7 years)
